Chemotherapy: PARP-I, Bevacizumab, and Ovarian Cytotoxics
Chemotherapy: PARP-I, Bev, Ovarian Cytotoxics
In this episode, we discuss antineoplastic agents for ovarian cancer. We discuss PARP-inhibitors, homologous recombination deficiency, bevacizumab, as well as new cytotoxic chemotherapy used in the treatment of ovarian cancers.
Ovary Part 7
In part 7 of our ovarian cancer series, we discuss surgical considerations in ovarian cancer, including patient and disease-specific factors that can influence surgical decision making, methods to predict optimal cytoreduction, and the utility of secondary cytoreduction.